Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Abstract Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13. Methods We undertook studies to compare i...

Full description

Bibliographic Details
Main Authors: Angela J. Okragly, Aya Ryuzoji, Isabella Wulur, Montanea Daniels, Robert D. Van Horn, Chetan N. Patel, Robert J. Benschop
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Interleukin-13
In vitro
Lebrikizumab
Mechanism of action
Online Access:https://doi.org/10.1007/s13555-023-00947-7

Internet

https://doi.org/10.1007/s13555-023-00947-7

Similar Items